International Isotopes Inc
OTC:INIS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
International Isotopes Inc
OTC:INIS
|
35.6m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
189.6B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
149.1B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.8B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.6B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.9B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.5B HKD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
International Isotopes Inc
Glance View
International Isotopes, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 30 full-time employees. Its segments include Nuclear Medicine Standards, which consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging, patient positioning, and calibration or operational testing of dose-measuring equipment for the nuclear pharmacy industry; Cobalt Products, which includes management of a cobalt irradiation contract, fabrication of cobalt capsules for teletherapy or irradiation devices, and recycling of expended cobalt sources; Radiochemical Products, which includes production and distribution of Iodine-131 generic drug product and isotopically pure radiochemicals; Fluorine Products, which is involved in the production of small-scale qualification samples of high purity fluoride gas, and Radiological Services, which consists of gemstone processing and source disposal services.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for International Isotopes Inc is 59.9%, which is below its 3-year median of 60.3%.
Over the last 3 years, International Isotopes Inc’s Gross Margin has increased from 57.6% to 59.9%. During this period, it reached a low of 55.8% on Mar 31, 2023 and a high of 63.1% on Sep 30, 2024.